Aarhus University Seal / Aarhus Universitets segl

Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study. / Gehrt, Lise; Rieckmann, Andreas; Kiraly, Nicholas; Jensen, Aksel Karl Georg; Aaby, Peter; Benn, Christine Stabell; Sørup, Signe.

I: The journal of allergy and clinical immunology. In practice, Bind 9, Nr. 4, 04.2021, s. 1520-1528.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Gehrt, L, Rieckmann, A, Kiraly, N, Jensen, AKG, Aaby, P, Benn, CS & Sørup, S 2021, 'Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study', The journal of allergy and clinical immunology. In practice, bind 9, nr. 4, s. 1520-1528. https://doi.org/10.1016/j.jaip.2020.09.024

APA

Gehrt, L., Rieckmann, A., Kiraly, N., Jensen, A. K. G., Aaby, P., Benn, C. S., & Sørup, S. (2021). Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study. The journal of allergy and clinical immunology. In practice, 9(4), 1520-1528. https://doi.org/10.1016/j.jaip.2020.09.024

CBE

Gehrt L, Rieckmann A, Kiraly N, Jensen AKG, Aaby P, Benn CS, Sørup S. 2021. Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study. The journal of allergy and clinical immunology. In practice. 9(4):1520-1528. https://doi.org/10.1016/j.jaip.2020.09.024

MLA

Vancouver

Gehrt L, Rieckmann A, Kiraly N, Jensen AKG, Aaby P, Benn CS o.a. Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study. The journal of allergy and clinical immunology. In practice. 2021 apr;9(4):1520-1528. https://doi.org/10.1016/j.jaip.2020.09.024

Author

Gehrt, Lise ; Rieckmann, Andreas ; Kiraly, Nicholas ; Jensen, Aksel Karl Georg ; Aaby, Peter ; Benn, Christine Stabell ; Sørup, Signe. / Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study. I: The journal of allergy and clinical immunology. In practice. 2021 ; Bind 9, Nr. 4. s. 1520-1528.

Bibtex

@article{680ab7b96935425dbde6c7cfea1ab768,
title = "Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study",
abstract = "BACKGROUND: An Australian study including 4433 children found that delayed Diphtheria-Tetanus-acellular Pertussis-containing vaccination was associated with reduced risk of developing atopic dermatitis (AD) before age 1 year.OBJECTIVE: We assessed whether delayed vaccination against diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b (Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b [DTaP]) was associated with a reduced risk of new cases of AD before age 1 year in Denmark.METHODS: We used nationwide registers to follow 883,160 children born in Denmark from 1997 to 2012. Binary regression models adjusting for potential confounding factors were applied to estimate relative risks (adjusted relative risks [aRRs]) of developing AD among children with delayed DTaP vaccination (defined as given 1 month or more after the recommended age) compared with timely vaccinated children.RESULTS: Among 143,429 children with a delayed first dose of DTaP, 4,847 (3.4%) developed AD between age 4 months and 1 year, compared with 27,628 (3.7%) among 739,731 children not having delayed DTaP (aRR 0.94; 95% CI, 0.91-0.97). The aRR was 0.94 (95% CI, 0.90-0.99) for children with a delayed second dose, and the aRR was 0.88 (95% CI, 0.82-0.93) when comparing children with delayed first and second doses with all timely vaccinated children.CONCLUSIONS: The results support the hypothesis that delayed vaccination with DTaP is associated with reduced risk of developing new cases of AD after age 4 months. The dose-dependent relationship strengthens the evidence of a causal relationship. Some countries are introducing maternal pertussis vaccination and delaying the first dose of DTaP, providing a possibility for further testing the hypothesis.",
author = "Lise Gehrt and Andreas Rieckmann and Nicholas Kiraly and Jensen, {Aksel Karl Georg} and Peter Aaby and Benn, {Christine Stabell} and Signe S{\o}rup",
note = "Copyright {\textcopyright} 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.",
year = "2021",
month = apr,
doi = "10.1016/j.jaip.2020.09.024",
language = "English",
volume = "9",
pages = "1520--1528",
journal = "The journal of allergy and clinical immunology. In practice",
issn = "2213-2201",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study

AU - Gehrt, Lise

AU - Rieckmann, Andreas

AU - Kiraly, Nicholas

AU - Jensen, Aksel Karl Georg

AU - Aaby, Peter

AU - Benn, Christine Stabell

AU - Sørup, Signe

N1 - Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

PY - 2021/4

Y1 - 2021/4

N2 - BACKGROUND: An Australian study including 4433 children found that delayed Diphtheria-Tetanus-acellular Pertussis-containing vaccination was associated with reduced risk of developing atopic dermatitis (AD) before age 1 year.OBJECTIVE: We assessed whether delayed vaccination against diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b (Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b [DTaP]) was associated with a reduced risk of new cases of AD before age 1 year in Denmark.METHODS: We used nationwide registers to follow 883,160 children born in Denmark from 1997 to 2012. Binary regression models adjusting for potential confounding factors were applied to estimate relative risks (adjusted relative risks [aRRs]) of developing AD among children with delayed DTaP vaccination (defined as given 1 month or more after the recommended age) compared with timely vaccinated children.RESULTS: Among 143,429 children with a delayed first dose of DTaP, 4,847 (3.4%) developed AD between age 4 months and 1 year, compared with 27,628 (3.7%) among 739,731 children not having delayed DTaP (aRR 0.94; 95% CI, 0.91-0.97). The aRR was 0.94 (95% CI, 0.90-0.99) for children with a delayed second dose, and the aRR was 0.88 (95% CI, 0.82-0.93) when comparing children with delayed first and second doses with all timely vaccinated children.CONCLUSIONS: The results support the hypothesis that delayed vaccination with DTaP is associated with reduced risk of developing new cases of AD after age 4 months. The dose-dependent relationship strengthens the evidence of a causal relationship. Some countries are introducing maternal pertussis vaccination and delaying the first dose of DTaP, providing a possibility for further testing the hypothesis.

AB - BACKGROUND: An Australian study including 4433 children found that delayed Diphtheria-Tetanus-acellular Pertussis-containing vaccination was associated with reduced risk of developing atopic dermatitis (AD) before age 1 year.OBJECTIVE: We assessed whether delayed vaccination against diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b (Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b [DTaP]) was associated with a reduced risk of new cases of AD before age 1 year in Denmark.METHODS: We used nationwide registers to follow 883,160 children born in Denmark from 1997 to 2012. Binary regression models adjusting for potential confounding factors were applied to estimate relative risks (adjusted relative risks [aRRs]) of developing AD among children with delayed DTaP vaccination (defined as given 1 month or more after the recommended age) compared with timely vaccinated children.RESULTS: Among 143,429 children with a delayed first dose of DTaP, 4,847 (3.4%) developed AD between age 4 months and 1 year, compared with 27,628 (3.7%) among 739,731 children not having delayed DTaP (aRR 0.94; 95% CI, 0.91-0.97). The aRR was 0.94 (95% CI, 0.90-0.99) for children with a delayed second dose, and the aRR was 0.88 (95% CI, 0.82-0.93) when comparing children with delayed first and second doses with all timely vaccinated children.CONCLUSIONS: The results support the hypothesis that delayed vaccination with DTaP is associated with reduced risk of developing new cases of AD after age 4 months. The dose-dependent relationship strengthens the evidence of a causal relationship. Some countries are introducing maternal pertussis vaccination and delaying the first dose of DTaP, providing a possibility for further testing the hypothesis.

U2 - 10.1016/j.jaip.2020.09.024

DO - 10.1016/j.jaip.2020.09.024

M3 - Journal article

C2 - 33011301

VL - 9

SP - 1520

EP - 1528

JO - The journal of allergy and clinical immunology. In practice

JF - The journal of allergy and clinical immunology. In practice

SN - 2213-2201

IS - 4

ER -